PTC Therapeutics, Inc. Files 10-Q for Period Ending March 31, 2024

TL;DR

<b>PTC Therapeutics, Inc. filed its quarterly report (10-Q) for the period ending March 31, 2024, detailing its financial status and business operations.</b>

AI Summary

PTC THERAPEUTICS, INC. (PTCT) filed a Quarterly Report (10-Q) with the SEC on April 25, 2024. PTC Therapeutics, Inc. reported financial results for the quarter ended March 31, 2024. The company's fiscal year ends on December 31. The filing is a 10-Q, indicating a quarterly report. The filing was submitted on April 25, 2024. The company's principal business is in Pharmaceutical Preparations.

Why It Matters

For investors and stakeholders tracking PTC THERAPEUTICS, INC., this filing contains several important signals. This 10-Q filing provides investors with an updated view of PTC Therapeutics' financial performance and operational status for the first quarter of 2024. Understanding the details within this report is crucial for assessing the company's current financial health, strategic direction, and potential risks moving forward.

Risk Assessment

Risk Level: medium — PTC THERAPEUTICS, INC. shows moderate risk based on this filing. The company operates in the pharmaceutical preparations industry, which is subject to significant regulatory oversight, lengthy development cycles, and intense competition, posing inherent risks to financial performance and market position.

Analyst Insight

Investors should review the detailed financial statements and risk factors in this 10-Q to understand PTC Therapeutics' performance and outlook for the remainder of 2024.

Key Numbers

• 2024-03-31 — Reporting Period End Date (CONFORMED PERIOD OF REPORT)
• 2024-04-25 — Filing Date (FILED AS OF DATE)
• 76653960 — Value 1 (2024 Q1)
• 75708889 — Value 2 (2023 Q1)

Key Players & Entities

• PTC THERAPEUTICS, INC. (company) — FILER
• 0001070081 (company) — CENTRAL INDEX KEY
• 2834 (company) — STANDARD INDUSTRIAL CLASSIFICATION
• DE (company) — STATE OF INCORPORATION
• 1231 (company) — FISCAL YEAR END
• 10-Q (company) — FORM TYPE
• 1934 Act (regulator) — SEC ACT
• 001-35969 (company) — SEC FILE NUMBER

FAQ

Risk Factors

• Regulatory Risks [high — regulatory]: The pharmaceutical industry is subject to extensive regulation by government agencies, which can impact product development, approval, manufacturing, and marketing.
• Market Competition [high — market]: The company faces intense competition from other pharmaceutical and biotechnology companies, which can affect market share and pricing.
• Financial Performance [medium — financial]: The company's ability to achieve profitability and manage its cash flow is subject to various factors, including product sales, research and development costs, and potential acquisitions.

Key Dates

• 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
• 2024-04-25: Filing Date — Date the 10-Q was officially filed with the SEC.

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share PTCT Nasdaq Glo

Filing Documents

• tmb-20240331x10q.htm (10-Q) — 2254KB
• tmb-20240331xex10d1.htm (EX-10.1) — 227KB
• tmb-20240331xex31d1.htm (EX-31.1) — 11KB
• tmb-20240331xex31d2.htm (EX-31.2) — 10KB
• tmb-20240331xex32d1.htm (EX-32.1) — 6KB
• tmb-20240331xex32d2.htm (EX-32.2) — 6KB
• tmb-20240331xex10d1001.jpg (GRAPHIC) — 6KB
• tmb-20240331xex10d1002.jpg (GRAPHIC) — 19KB
• 0001558370-24-005782.txt (&nbsp;) — 12613KB
• tmb-20240331.xsd (EX-101.SCH) — 81KB
• tmb-20240331_cal.xml (EX-101.CAL) — 73KB
• tmb-20240331_def.xml (EX-101.DEF) — 401KB
• tmb-20240331_lab.xml (EX-101.LAB) — 769KB
• tmb-20240331_pre.xml (EX-101.PRE) — 609KB
• tmb-20240331x10q_htm.xml (XML) — 2558KB

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements (unaudited)

Item 1. Financial Statements (unaudited) 4

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 40

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 56

Controls and Procedures

Item 4. Controls and Procedures 56

—OTHER INFORMATION

PART II—OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 57

Risk Factors

Item 1A. Risk Factors 57

Other Information

Item 5. Other Information 57

Exhibits

Item 6. Exhibits 61 i Table of Contents

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Quarterly Report on Form 10-Q, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "might," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The forward-looking statements in this Quarterly Report on Form 10-Q include, among other things, statements about: our ability to negotiate, secure and maintain adequate pricing, coverage and reimbursement terms and processes on a timely basis, or at all, with third-party payors for our products or product candidates that we commercialize or may commercialize in the future; our expectations with respect to the European Commission's potential adoption of the Committee for Medicinal Products for Human Use's negative opinion for the renewal of the conditional marketing authorization for Translarna TM (ataluren) for the treatment of nonsense mutation Duchenne muscular dystrophy, or nmDMD, in the European Economic Area, or EEA, following a re-examination procedure and our ability to maintain such conditional marketing authorization or identify other potential mechanisms in which we may provide Translarna to nmDMD patients in the EEA ; Our ability to maintain our marketing authorizations in other jurisdictions in which Translarna has been approved; our ability to utilize results from Study 041 and from our international drug registry study to support a marketing approval for Transla

—FINANCIAL INFORMATION

PART I—FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements. PTC Therapeutics, Inc. Consolidated Balance Sheets (unaudited) In thousands (except shares) March 31, December 31, 2024 2023 Assets Current assets: Cash and cash equivalents $ 548,355 $ 594,001 Marketable securities 336,458 282,738 Trade and royalty receivables, net 197,660 160,822 Inventory, net 30,058 30,577 Prepaid expenses and other current assets 56,207 150,491 Total current assets 1,168,738 1,218,629 Fixed assets, net 92,779 87,089 Intangible assets, net 330,040 379,497 Goodwill 82,341 82,341 Operating lease ROU assets 91,186 91,896 Deposits and other assets 24,545 36,246 Total assets $ 1,789,629 $ 1,895,698 Liabilities and stockholders' deficit Current liabilities: Accounts payable and accrued expenses $ 330,924 $ 391,983 Deferred revenue — 801 Operating lease liabilities- current 14,572 13,002 Finance lease liabilities- current 1,948 3,000 Liability for sale of future royalties- current 227,102 194,314 Total current liabilities 574,546 603,100 Long-term debt 284,512 284,213 Contingent consideration payable 36,200 36,300 Deferred tax liability 55,904 55,905 Operating lease liabilities- noncurrent 104,837 97,627 Finance lease liabilities- noncurrent 15,574 17,184 Liability for sale of future royalties- noncurrent 1,611,831 1,619,783 Other long-term liabilities 141 141 Total liabilities 2,683,545 2,714,253 Stockholders' deficit: Common stock, $ 0.001 par value. Authorized 250,000,000 shares; issued and outstanding 76,653,960 shares at March 31, 2024. Authorized 250,000,000 shares; issued and outstanding 75,708,889 shares at December 31, 2023. 76 75 Additional paid-in capital 2,486,722 2,466,233 Accumulated other comprehensive loss ( 5,560 ) ( 1,285 ) Accumulated deficit ( 3,375,154 ) ( 3,283,578 ) Total stockholders' deficit ( 893,916 ) ( 818,555 ) Total liabili

Notes to Consolidated Financial Statements (unaudited)

Notes to Consolidated Financial Statements (unaudited) March 31, 2024 In thousands (except share and per share amounts unless otherwise noted) 1. The Company PTC Therapeutics, Inc. (the "Company" or "PTC") is a global biopharmaceutical company focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. PTC's ability to innovate to identify new therapies and to globally commercialize products is the foundation that drives investment in a robust and diversified pipeline of transformative medicines. PTC's mission is to provide access to best-in-class treatments for patients who have little to no treatment options. PTC's strategy is to leverage its strong scientific and clinical expertise and global commercial infrastructure to bring therapies to patients. PTC believes that this allows it to maximize value for all of its stakeholders. PTC has a diversified therapeutic portfolio pipeline that includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy ("DMD"), a rare, life threatening disorder. Translarna has marketing authorization in the European Economic Area (the "EEA") for the treatment of nonsense mutation Duchenne muscular dystrophy ("nmDMD") in ambulatory patients aged 2 years and older. Translarna also has marketing authorization in Russia for the treatment of nmDMD in patients aged two years and older and in Brazil for the treatment of nmDMD in ambulatory patients two years and older and for continued treatment of patients that become non-ambulatory, as well as in various other countries. Emflaza is approved

View Full Filing

View this 10-Q filing on SEC EDGAR